Clinical Trials
Sep 13, 2026 · 1 min read · 41,995 views
Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
A
Aiden Brooks
Editorial · Sep 13, 2026
Roche's Lunsumio plus Revlimid beat Rituxan/Revlimid in Phase 3 CELESTIMO trial, supporting full FDA approval and second-line follicular lymphoma label expansion
← Previous
Insurers play catch-up
Next →
FDA offers little comment on Grail cancer test ahead of adcomm
